Britain and America have signed a important commercial pact that will keep no tariffs on UK medicine exports entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the public health system. This move secures that tariffs on these key goods will remain at zero for a duration of the next three years.
This agreement is in response to previous threats to hike tariffs on patented drug products, with increases floated reaching 100%.
"This deal between the Britain bolsters the global environment for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," a statement noted.
Commercial Importance
Pharmaceuticals are one of the Britain's biggest goods shipped to the US, which is by far the biggest destination for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This guarantee protects work, boosts investment and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key British Pledges
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. Previously, rebates were more than twenty percent.
Industry Background
The deal comes amid a long-running dispute between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
These tensions were heightened by assertions that American customers were paying significantly more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or abandoned, while substantial expansions have been announced toward US facilities.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the past decade.
